Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
How do you approach a patient with discordant Fibroscan and serologic testing for fibrosis?
Related Questions
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
What is your approach to the use of lipoprotein(a) as part of the cardiometabolic profile of a patient suspected to have or with MASLD/MASH?
In a patient with low (or normal) BMI but findings of steatosis on imaging, no cardiometabolic comorbidities, and very elevated CAP scores, what are your next diagnostic and therapeutic steps to identify the cause of their steatosis and subsequent management?
In patients with Met-ALD, would you still offer the same therapeutic/pharmacologic treatments (ex: GIP/GLP-1 agonists, Resmetirom, ex) for management of their disease as in a "pure" MASLD patient?
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
In what scenario would you opt to perform an MRI-PDFF in a patient with MASLD/MASH or in whom you suspect has this? Why would you opt for this over a Fibroscan or other NILDA?
How would you approach GLP-1/GIP agonist use for MASLD management in a patient who had a prior episode of pancreatitis?
In what kind of patient scenario would you consider testing for inherited disorders of lipid metabolism in the evaluation of a patient with MASLD? What are you looking for clinically and in their workup and how do you proceed?
What clinical, imaging, or serologic markers would be an indication to you to stop GLP-1 therapy for management of MASLD?
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
